Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Adolescents and young adults with newly diagnosed primary immune thrombocytopenia
Haematologica, Volume 108, No. 10, Year 2023
Notification
URL copied to clipboard!
Description
Current immune thrombocytopenia (ITP) guidelines target children and adults, leading to oversimplification. Adolescents and young adults (AYAS) comprise a separate group with distinct health and psychosocial issues. This study aimed to describe the clinical presentation and therapeutic strategies of ITP among AYAS. We analyzed data from two large ITP registries (PARC-ITP; CARMEN-France) and included newly diagnosed ITP patients (aged 12-25 years) with an initial platelet counts of <100×109/L. Patients with secondary ITP or non-immune thrombocytopenia (n=57) and pregnant women (n=10) were excluded. Of the 656 cases of AYAS with primary ITP registered from 2004 up to 2021, 12-month follow-up data were available for 72%. The initial median platelet count was 12×109/L. In 109 patients (17%), the diagnosis was incidental, without documented bleeding. Apart from gynecological bleeding, the clinical and therapeutical characteristics of females and males were similar. Platelet-enhancing drugs were reported in 66%, 45%, and 30% of patients at diagnosis, 1-6 months, and 6-12 months after diagnosis, respectively. Corticosteroids were the preferred treatment at all time points. At 12 months, 50% of all patients developed chronic ITP. In the subgroup of patients with initial severe thrombocytopenia (<20×109/L), those receiving frontline treatment had a higher remission rate at 1 year than those who followed an initial watch-and-wait strategy (53% and 32%; P<0.05). Our analysis indicates that the remission rate at 1 year may be associated with the initial treatment strategy. This hypothesis must be confirmed in prospective studies. ©2023 Ferrata Storti Foundation Published under a CC BY-NC license.
Authors & Co-Authors
Schifferli, Alexandra
Switzerland, Basel
Universitäts-kinderspital Beider Basel
Moulis, Guillaume
Unknown Affiliation
Godeau, Bertrand
France, Creteil
Université Paris-est Créteil Val de Marne
Leblanc, Thierry M.
France, Paris
Ap-hp Assistance Publique - Hopitaux de Paris
Aladjidi, Nathalie
France, Paris
Inserm
Michel, Marc
France, Creteil
Université Paris-est Créteil Val de Marne
Leverger, Guy G.
France, Paris
Sorbonne Université
ElAlfy, Mohsen Saleh
Egypt, Cairo
Ain Shams University
Grainger, John David
United Kingdom, Manchester
Health Innovation Manchester
Chitlur, Meera B.
United States, Detroit
Children's Hospital of Michigan
Holzhauer, Susanne
Germany, Berlin
Charité – Universitätsmedizin Berlin
Imbach, Paul A.
Switzerland, Basel
Universitäts-kinderspital Beider Basel
Kühne, Thomas
Switzerland, Basel
Universitäts-kinderspital Beider Basel
Statistics
Citations: 3
Authors: 13
Affiliations: 9
Identifiers
Doi:
10.3324/haematol.2022.282524
ISSN:
03906078
Research Areas
Maternal And Child Health
Study Design
Cohort Study
Participants Gender
Female